Projet AEGIS (Horizon 2020, appel à projets 2015)
Action : Doctoral Networks
Panel : Chemistry
Statut du projet : CLOSED

The development of effective novel drugs - especially for rare and neglected diseases - is one of the biggest challenges of the upcoming decades, as illustrated by the recent Ebola outbreak. Moreover, European innovation in new drug registrations is dramatically falling behind compared to the US and Asia. The principal aim of the AEGIS ITN is to implement the first comprehensive, intersectoral cross-disciplinary and structured curriculum for doctoral students in the European Research Area by establishing a unique training platform for the next generation of European researchers in early drug discovery. A significant added value is provided through networking with key European pharmaceutical companies. A key research aim of AEGIS is improving the efficiency and success of early stage drug development by combining innovative methods and techniques to tackle difficult but promising targets (i.e. protein-protein interactions), as potentially valuable drug targets are often neglected due to the high risk associated with their validation. The consortium joins leading academic and industry researchers in an open innovation environment for innovative drug development in Europe. It is supported by several additional partners and stakeholders in the field. Integrated training of the fellows takes place at the host institute and by secondments, research schools and individual training within the AEGIS network. The scientific training includes complementary skills, management, intellectual property rights, fund raising, communication and career planning. AEGIS will improve the availability of a highly skilled workforce for European industries and research, greatly enhance the employability and the career perspectives of young researchers for academia as well as for industry, and will be the seed of a sustainable development in innovative drug discovery, in particular for rare and neglected diseases.

Mots clés : early stage drug discovery, fragment based drug discovery, drug development, rare, neglected diseases, nmr spectroscopy, x ray crystallography, protein protein interactions, allosteric drugs

Participants :
- Unternehmertum gmbh (Allemagne) — Partner, organization partner, Autres, subvention : 0.0 €
- Ruhr University Bochum (Allemagne) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Philipps University of Marburg (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 498432.96 €
- Giotto Biotech (Italy) (Italie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 258061.32 €
- AstraZeneca (Sweden) (Suède) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 263659.32 €
- Institut national de la santé et de la recherche médicale (France) — Partner, organization partner, Recherche, subvention : 0.0 €
- University of Pittsburgh (Etats-Unis) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Helmholtz Zentrum München (Allemagne) — Coordinator, beneficiary, Recherche, subvention : 498432.96 €
- Board of the Swiss Federal Institutes of Technology (Suisse) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 265226.76 €
- Jagiellonian University (Pologne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 224137.44 €
- Institut Pasteur (France) — Partner, beneficiary, Recherche, subvention : 525751.2 €
- Technical University of Munich (Allemagne) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Max Planck Society (Allemagne) — Partner, organization partner, Recherche, subvention : 0.0 €
- University of Groningen (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 510748.56 €
- Eindhoven University of Technology (Pays-Bas) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- University of Florence (Italie) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Astex (Espagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Ridgeview instruments ab (Suède) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 263659.32 €
- Telesispharma (Pays-Bas) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Boeters & lieck (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Enamine (Ukraine) (Ukraine) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Jagiellonian University (Pologne) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Uppsala University (Suède) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 263659.32 €
- Novartis (Switzerland) (Suisse) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 265226.76 €
- Eurordis - rare diseases europe (France) — Partner, organization partner, Autres, subvention : 0.0 €